 - Female subjects of childbearing potential and non-sterile males must agree to practice at least one of the following methods of birth control with partners throughout the study and for 3 months after discontinuing BGB-3111 or 18 months following obinutuzumab treatment, whichever is longer: total abstinence from sexual intercourse, double barrier contraception, intra uterine device IUD or hormonal contraceptive initiated at least 3 months prior to first administration of study drug. 